Skip to main navigation Skip to search Skip to main content

Validation of a model predicting the effect of 2,3-dimercaptosuccinic acid (DMSA) chelation therapy in patients intoxicated by lead

  • Jan C. Van Eijkeren
  • , Irma de Vries
  • , Sally M. Bradberry
  • , J. Allister Vale
  • , Harvey J., III Clewell
  • , Claudine C. Hunault

Research output: Contribution to journal › Meeting Abstract › Academic

Abstract

In situations where lead poisoning occurs, the decision as to when
to start chelation therapy and the choice of the most efficient chelator is never straightforward. Kinetic models may assist clinical
toxicologists in their decisions. We developed a Chelation Therapy
Lead (CTL) Model in order to simulate the effect of DMSA chelation
in lead poisoning. We aimed at validating the predictions of this
model with data from a previously published case report.
The CTL Model combines a two-compartment kinetic model for
DMSA and an existing kinetic lead model for humans. The accuracy of the CTL Model’s predictions was assessed by simulating data
from a published case report. The patient was a 27-year-old woman,
planning for pregnancy, but diagnosed with chronic lead intoxication due to ingestion of Ayurvedic medication. It was decided to
delay conception and first treat her lead poisoning. She entered
a follow-up program in an occupational clinic for chelation treatment. The patient’s pre-chelation lead level in blood was 58 g/dL.
She received eighteen 19-day courses of DMSA, 500 mg twice daily,
over 2 years, with 2–3 week rest periods.
The predicted ranges of the blood lead concentration after
the second and last chelation treatments were 3–15 g/dL and
2–8 g/dL, respectively, while the measured blood lead concentrations were 11 g/dL and 5 g/dL.
The CTL Model was able to predict the blood lead concentration
after chelation by DMSA therapy in this case report.
Original languageEnglish
Pages (from-to)S281-S281
JournalToxicology Letters
Volume280
DOIs
Publication statusPublished - 20 Oct 2017

Fingerprint

Dive into the research topics of 'Validation of a model predicting the effect of 2,3-dimercaptosuccinic acid (DMSA) chelation therapy in patients intoxicated by lead'. Together they form a unique fingerprint.

Cite this